Enhertu-Induced Resistant Tumor Models
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies. However, primary and secondary resistance is frequently observed, and development of next generation ADCs necessitates the establishment of resistant tumor models. WuXi AppTec offers validated, Enhertu-induced resistant tumor models to support project teams focused on ADC therapeutics against breast and lung cancer.
Learn about our comprehensive platform of ADC services by clicking HERE
Enhertu-induced resistant tumor models
Related Content
Antibody-targeted therapies—including antibody-drug conjugates (ADCs), antibody-oligonucleotide conjugates (AOCs), and degrader-antibody conjugates (DACs)—are reshaping precision medicine by enabling highly selective delivery...
VIEW RESOURCEAntibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics, but their complex structure poses significant development and safety challenges....
VIEW RESOURCE